Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518080 | 0.87 | FFAR4 (0.56) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL10656287 | 0.87 | GPR17 (0.50) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL10654918 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL5036037 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL10741844 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL11663270 | 0.86 | TDP1 (0.54) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL11627411 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL11628716 | 0.86 | TSHR (0.58) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL10655575 | 0.84 | TDP1 (0.44) | ALDH1A1MEN1POLBKMT2APKM | |
| SCHEMBL10735678 | 0.83 | ALPL (0.44) | ALDH1A1MEN1POLBKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1966495-B | Method for preparing 5-(4- fluobenzene sulphonyloxy) benzimidazole-2-amido methyl formate | CHANGZHOU YABANG QIHUI FINE CHEMICALS CO LTD | 2010-06-16 | — | — | CN | claimed |
| CN-1966495-A | Method for preparing 5-(4- fluobenzene sulphonyloxy) benzimidazole-2-amido methyl formate | CHANGZHOU YABANG QIHUI FINE CH (CN) | 2007-05-23 | — | — | CN | claimed |
| CN-1966495-B | Method for preparing 5-(4- fluobenzene sulphonyloxy) benzimidazole-2-amido methyl formate | CHANGZHOU YABANG QIHUI FINE CHEMICALS CO LTD | 2010-06-16 | — | — | CN | disclosed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| CN-100346786-C | Substituted benzimidazole compounds and their use in the treatment of cancer | AVENTIS PHARMA SA (FR) | 2007-11-07 | — | — | CN | disclosed |
| CN-1966495-A | Method for preparing 5-(4- fluobenzene sulphonyloxy) benzimidazole-2-amido methyl formate | CHANGZHOU YABANG QIHUI FINE CH (CN) | 2007-05-23 | — | — | CN | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| CN-1558761-A | substituted benzimidazole compounds and their use in the treatment of cancer | �㶫��������ҽҩ�ɷ�����˾ | 2004-12-29 | — | — | CN | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
| EP-1298125-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | Aventis Pharma S.A. (FR) | 2003-04-02 | — | — | EP | disclosed |
| EP-0115039-B1 | SUBSTITUTED PHENYLSULFONYLOXYBENZIMIDAZOLE CARBAMATES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-10 | — | — | EP | disclosed |
| US-4639463-A | Substituted phenylsulfonyloxybenzimidazolecarbamates and anthelmintic compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-27 | — | — | US | disclosed |
| EP-0115039-A1 | Substituted phenylsulfonyloxybenzimidazole carbamates, process for their preparation and their application as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | ALDH1A1 1134/4885MEN1 3925/4885POLB 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.